UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $615
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice TargetHot
UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $585 to $615.
UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $585 to $615.